Advertisement

Topics

FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors

01:00 EDT 17 Apr 2018 | Hoffmann-La Roche Ltd

Roche today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra® (emicizumab-kxwh) for people with haemophilia A without factor VIII inhibitors.

Original Article: FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors

NEXT ARTICLE

More From BioPortfolio on "FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...